Skip to Content
Merck
  • Semmaphorin 3 A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells.

Semmaphorin 3 A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells.

Nature communications (2024-04-13)
Mike B Barnkob, Yale S Michaels, Violaine André, Philip S Macklin, Uzi Gileadi, Salvatore Valvo, Margarida Rei, Corinna Kulicke, Ji-Li Chen, Vitul Jain, Victoria K Woodcock, Huw Colin-York, Andreas V Hadjinicolaou, Youxin Kong, Viveka Mayya, Julie M Mazet, Gracie-Jennah Mead, Joshua A Bull, Pramila Rijal, Christopher W Pugh, Alain R Townsend, Audrey Gérard, Lars R Olsen, Marco Fritzsche, Tudor A Fulga, Michael L Dustin, E Yvonne Jones, Vincenzo Cerundolo
ABSTRACT

Semaphorin-3A (SEMA3A) functions as a chemorepulsive signal during development and can affect T cells by altering their filamentous actin (F-actin) cytoskeleton. The exact extent of these effects on tumour-specific T cells are not completely understood. Here we demonstrate that Neuropilin-1 (NRP1) and Plexin-A1 and Plexin-A4 are upregulated on stimulated CD8+ T cells, allowing tumour-derived SEMA3A to inhibit T cell migration and assembly of the immunological synapse. Deletion of NRP1 in both CD4+ and CD8+ T cells enhance CD8+ T-cell infiltration into tumours and restricted tumour growth in animal models. Conversely, over-expression of SEMA3A inhibit CD8+ T-cell infiltration. We further show that SEMA3A affects CD8+ T cell F-actin, leading to inhibition of immune synapse formation and motility. Examining a clear cell renal cell carcinoma patient cohort, we find that SEMA3A expression is associated with reduced survival, and that T-cells appear trapped in SEMA3A rich regions. Our study establishes SEMA3A as an inhibitor of effector CD8+ T cell tumour infiltration, suggesting that blocking NRP1 could improve T cell function in tumours.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Jasplakinolide, ≥97% (HPLC)
Sigma-Aldrich
(±)-Blebbistatin, (±)-Blebbistatin, CAS 674289-55-5, is a cell-permeable, selective, and reversible inhibitor of nonmuscle myosin II. Blocks cell blebbing and disrupts cell migration & cytoKinesis in vertebrate cells.